Patents by Inventor Yuji SHOYA
Yuji SHOYA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230192890Abstract: Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10?9 or less. Optionally, the anti-PAD4 antibody and a TNF? inhibitor are used in combination.Type: ApplicationFiled: September 19, 2022Publication date: June 22, 2023Inventors: Mamoru SATO, Michiyuki YAMADA, Satoshi KANAZAWA, Masayoshi TOYOURA, Yuji SHOYA, Kenji SAITO, Chihiro YAMAZAKI
-
Patent number: 11447569Abstract: Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10?9 or less. Optionally, the anti-PAD4 antibody and a TNF? inhibitor are used in combination.Type: GrantFiled: March 7, 2016Date of Patent: September 20, 2022Assignees: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY, PHARMA FOODS INTERNATIONAL CO., LTD.Inventors: Mamoru Sato, Michiyuki Yamada, Satoshi Kanazawa, Masayoshi Toyoura, Yuji Shoya, Kenji Saito, Chihiro Yamazaki
-
Publication number: 20210340275Abstract: The present invention relates to an esophageal cancer marker and application thereof. The present invention relates to: a marker that includes Glypican-1 or an expression product thereof, or a fragment or derivative thereof, and serves to identify esophageal cancer; a detection agent that includes a substance that binds to Glypican-1 or an expression product thereof; and a composition that includes a Glypican-1 inhibitor and serves to prevent or treat esophageal cancer. Herein, Glypican-1 can be SEQ ID NO: 1 (nucleic acid sequence) or SEQ ID NO: 2 (amino acid sequence), or an equivalent thereof.Type: ApplicationFiled: June 30, 2021Publication date: November 4, 2021Inventors: Tetsuji Naka, Satoshi Serada, Minoru Fujimoto, Masayoshi Toyoura, Yuji Shoya
-
Patent number: 10806787Abstract: The present invention provides an anti-FSTL1 antibody or a fragment or functional equivalent thereof, wherein the antibody recognizes an epitope in a region selected from the group consisting of amino acid positions 48 to 100, 148 to 162, 193 to 216, 205 to 228, and 272 to 289 of SEQ ID NO: 1 (amino acid sequence of human FSTL1). The present invention also provides a combination product of a FSTL1 suppressor and additional cancer treatment. It is understood that immune defect such as immunosuppression or immunodeficiency is effectively mitigated by the present invention.Type: GrantFiled: February 16, 2016Date of Patent: October 20, 2020Assignee: PHARMA FOODS INTERNATIONAL CO., LTD.Inventors: Chie Kudo, Masayoshi Toyoura, Akiko Ishida, Yuji Shoya, Chihiro Yamazaki
-
Publication number: 20190023781Abstract: According to the present disclosure there are provided compositions and methods for treating malignant tumors, including an anti-LSR (lipolysis stimulated lipoprotein receptor) antibody that comprises the presently disclosed antibody heavy and light chain complementarity determining region (CDR) sequences, or an antigen-binding fragment thereof, or a functional equivalent thereof. Further provided for treating an LSR-positive malignancy is an LSR antagonist or an LSR inhibitor such as a nucleic acid. Therapeutic administration of the anti-LSR antibody to a subject having an LSR-positive malignant tumor is also described.Type: ApplicationFiled: October 3, 2018Publication date: January 24, 2019Inventors: Tetsuji Naka, Satoshi Serada, Minoru Fujimoto, Masayoshi Toyoura, Yuji Shoya
-
Patent number: 10174111Abstract: According to the present disclosure there are provided compositions and methods for treating malignant tumors, including an anti-LSR (lipolysis stimulated lipoprotein receptor) antibody that comprises the presently disclosed antibody heavy and light chain complementarity determining region (CDR) sequences, or an antigen-binding fragment thereof, or a functional equivalent thereof. Further provided for treating an LSR-positive malignancy is an LSR antagonist or an LSR inhibitor such as a nucleic acid. Therapeutic administration of the anti-LSR antibody to a subject having an LSR-positive malignant tumor is also described.Type: GrantFiled: December 25, 2014Date of Patent: January 8, 2019Assignee: National University Corporation Kochi UniversityInventors: Tetsuji Naka, Satoshi Serada, Minoru Fujimoto, Masayoshi Toyoura, Yuji Shoya
-
Publication number: 20180362658Abstract: The present invention relates to an esophageal cancer marker and application thereof. The present invention relates to: a marker that includes Glypican-1 or an expression product thereof, or a fragment or derivative thereof, and serves to identify esophageal cancer; a detection agent that includes a substance that binds to Glypican-1 or an expression product thereof; and a composition that includes a Glypican-1 inhibitor and serves to prevent or treat esophageal cancer. Herein, Glypican-1 can be SEQ ID NO: 1 (nucleic acid sequence) or SEQ ID NO: 2 (amino acid sequence), or an equivalent thereof.Type: ApplicationFiled: August 14, 2018Publication date: December 20, 2018Inventors: Tetsuji Naka, Satoshi Serada, Minoru Fujimoto, Masayoshi Toyoura, Yuji Shoya
-
Patent number: 10077316Abstract: The present invention relates to an esophageal cancer marker and application thereof. The present invention relates to: a marker that includes Glypican-1 or an expression product thereof, or a fragment or derivative thereof, and serves to identify esophageal cancer; a detection agent that includes a substance that binds to Glypican-1 or an expression product thereof; and a composition that includes a Glypican-1 inhibitor and serves to prevent or treat esophageal cancer. Herein, Glypican-1 can be SEQ ID NO: 1 (nucleic acid sequence) or SEQ ID NO: 2 (amino acid sequence), or an equivalent thereof.Type: GrantFiled: December 25, 2014Date of Patent: September 18, 2018Assignee: National University Corporation, Kochi UniversityInventors: Tetsuji Naka, Satoshi Serada, Minoru Fujimoto, Masayoshi Toyoura, Yuji Shoya
-
Publication number: 20180044434Abstract: Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10?9 or less. Optionally, the anti-PAD4 antibody and a TNF? inhibitor are used in combination.Type: ApplicationFiled: March 7, 2016Publication date: February 15, 2018Inventors: Mamoru SATO, Michiyuki YAMADA, Satoshi KANAZAWA, Masayoshi TOYOURA, Yuji SHOYA, Kenji SAITO, Chihiro YAMAZAKI
-
Publication number: 20180021429Abstract: The present invention provides an anti-FSTL1 antibody or a fragment or functional equivalent thereof, wherein the antibody recognizes an epitope in a region selected from the group consisting of amino acid positions 48 to 100, 148 to 162, 193 to 216, 205 to 228, and 272 to 289 of SEQ ID NO: 1 (amino acid sequence of human FSTL1). The present invention also provides a combination product of a FSTL1 suppressor and additional cancer treatment. It is understood that immune defect such as immunosuppression or immunodeficiency is effectively mitigated by the present invention.Type: ApplicationFiled: February 16, 2016Publication date: January 25, 2018Applicant: PHARMA FOODS INTERNATIONAL CO., LTD.Inventors: Chie KUDO, Masayoshi TOYOURA, Akiko ISHIDA, Yuji SHOYA, Chihiro YAMAZAKI
-
Publication number: 20170066836Abstract: The present invention relates to an esophageal cancer marker and application thereof. The present invention relates to: a marker that includes Glypican-1 or an expression product thereof, or a fragment or derivative thereof, and serves to identify esophageal cancer; a detection agent that includes a substance that binds to Glypican-1 or an expression product thereof; and a composition that includes a Glypican-1 inhibitor and serves to prevent or treat esophageal cancer. Herein, Glypican-1 can be SEQ ID NO: 1 (nucleic acid sequence) or SEQ ID NO: 2 (amino acid sequence), or an equivalent thereof.Type: ApplicationFiled: December 25, 2014Publication date: March 9, 2017Inventors: Tetsuji NAKA, Satoshi SERADA, Minoru FUJIMOTO, Masayoshi TOYOURA, Yuji SHOYA
-
Publication number: 20170051056Abstract: The present invention makes it possible to obtain a novel therapeutic drug for malignant tumors. Specifically, the present invention provides a therapeutic drug for malignant tumors, said drug including an anti-LSR (lipolysis stimulated lipoprotein receptor) antibody or an antigen-binding fragment thereof, or a functional equivalent thereof, or an LSR inhibitor such as a nucleic acid. Said inhibitor uses a therapeutic drug for malignant tumors, said drug including an anti-LSR antibody, or an antigen-binding fragment thereof or a functional equivalent thereof. The inhibitor may also be an LSR antagonist. The abovementioned therapeutic drug may be administered to patients in whom the onset of an LSR-positive malignant tumor is judged to have occurred.Type: ApplicationFiled: December 25, 2014Publication date: February 23, 2017Inventors: Tetsuji NAKA, Satoshi SERADA, Minoru FUJIMOTO, Masayoshi TOYOURA, Yuji SHOYA